{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:43:47Z","timestamp":1780548227446,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Web of Science, Medline, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> databases were searched up to 8 August 2023. Randomized clinical trials of lebrikizumab treatment for moderate-to-severe AD were included by screening titles, abstracts, and papers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five studies involving 1,551 patients with AD were identified. Pooled analysis revealed significant improvements in the Eczema Area and Severity Index (EASI) score (SMD = \u22120.527; 95% CI = [\u22120.617, \u22120.436]), Investigator\u2019s Global Assessment (IGA) score (RR = 2.122; 95% CI = [1.803, 2.496]), Body Surface Area (BSA) score (SMD = \u22120.608; 95% CI = [\u22121.099, \u22120.118]), SCORing Atopic Dermatitis (SCORAD) score (SMD = \u22120.441; 95% CI = [\u22120.633, \u22120.250]). Moreover, Pruritus Numeric Rating Scale (P-NRS) score, Patient-oriented Eczema Measure (POEM) scores, Sleep-loss score and Dermatology Life Quality Index (DLQI) scores showed similar results. Adverse events (AEs) (RR = 0.984; 95% CI = [0.907, 1.068]) for lebrikizumab showed no statistically significant difference compared to placebo, with similar results for serious adverse events (SAEs) (RR = 0.748; 95% CI = [0.410, 1.364]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis reveals that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD, with the 250\u00a0mg Q2W dosage regimen appearing to be more advantageous.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1429709","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T04:24:32Z","timestamp":1731990272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinger","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haosong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","article-title":"Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial","volume":"160","author":"A","year":"2024","journal-title":"JAMA dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"adv00161","DOI":"10.2340\/00015555-3511","article-title":"Counting the burden: atopic dermatitis and health-related quality of life","volume":"100","author":"Ali","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad286","article-title":"The future is now: the global atopic dermatitis atlas (GADA)","author":"Arents","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1091271","DOI":"10.3389\/fmed.2022.1091271","article-title":"The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"9","author":"Bashrahil","year":"2022","journal-title":"Front. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaip.2020.12.007","article-title":"Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies","volume":"9","author":"Bawany","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis","volume":"24","author":"Bernardo","year":"2023","journal-title":"Am. J. Clin. Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2147\/CCID.S295672","article-title":"Managing atopic dermatitis with lebrikizumab - the evidence to date","volume":"15","author":"Labib","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet Lond Engl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1154949","DOI":"10.3389\/fphar.2023.1154949","article-title":"Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/JAA.S211032","article-title":"Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis","volume":"13","author":"Loh","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","article-title":"Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral centre","volume":"11","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B16","article-title":"Which clinical measurement tools for atopic dermatitis severity make the most sense in clinical practice?","author":"Narla","year":"2023","journal-title":"Dermat. Contact Atopic Occup. Drug"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and emerging systemic treatments for atopic dermatitis","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther. (Heidelb)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/ACI.0000000000000837","article-title":"Clinical phenotypes of adult atopic dermatitis and related therapies","volume":"22","author":"Patruno","year":"2022","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"adv00764","DOI":"10.2340\/actadv.v102.2075","article-title":"Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"102","author":"Sedeh","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.anai.2018.07.004","article-title":"Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J. Am. Acad. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br. J. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","article-title":"Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study","volume":"90","author":"Veverka","year":"2024","journal-title":"J. Am. Acad. Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J. Dermatol Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1429709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T04:24:36Z","timestamp":1731990276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1429709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":30,"alternative-id":["10.3389\/fphar.2024.1429709"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1429709","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"article-number":"1429709"}}